Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review

IF 2.4 3区医学 Q2 HEMATOLOGY Annals of Hematology Pub Date : 2025-04-09 DOI:10.1007/s00277-025-06351-9

Ying Wang, Qiong Liu, Chun-li Xu, Dong-ping Huang, Yu Chen

{"title":"Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review","authors":"Ying Wang, Qiong Liu, Chun-li Xu, Dong-ping Huang, Yu Chen","doi":"10.1007/s00277-025-06351-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Central nervous system (CNS) blast crisis in chronic myeloid leukemia (CML) is rare and presents a significant treatment challenge due to the limited ability of many systemic therapies to penetrate the blood-brain barrier (BBB). This case highlights the need for effective treatment strategies.</p><h3>Case report</h3><p>This case report describes a 43-year-old man diagnosed with CML who developed a CNS blast crisis followed by bone marrow relapse while receiving flumatinib.</p><h3>Discussion</h3><p>The patient achieved complete remission (CR) in both the bone marrow and CNS after receiving a combination of blinatumomab and olverembatinib, along with weekly intrathecal chemotherapy.</p><h3>Conclusions</h3><p>The combination of blinatumomab, olverembatinib, and concurrent intrathecal chemotherapy may be an effective treatment strategy for CML progression, particularly in cases with CNS involvement.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"104 5","pages":"3047 - 3051"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141131/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-025-06351-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Central nervous system (CNS) blast crisis in chronic myeloid leukemia (CML) is rare and presents a significant treatment challenge due to the limited ability of many systemic therapies to penetrate the blood-brain barrier (BBB). This case highlights the need for effective treatment strategies.

Case report

This case report describes a 43-year-old man diagnosed with CML who developed a CNS blast crisis followed by bone marrow relapse while receiving flumatinib.

Discussion

The patient achieved complete remission (CR) in both the bone marrow and CNS after receiving a combination of blinatumomab and olverembatinib, along with weekly intrathecal chemotherapy.

Conclusions

The combination of blinatumomab, olverembatinib, and concurrent intrathecal chemotherapy may be an effective treatment strategy for CML progression, particularly in cases with CNS involvement.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

布利纳单抗联合欧维巴替尼联合鞘内化疗成功治疗慢性髓系白血病复发合并中枢神经系统母细胞危像1例报告并文献复习。

目的：慢性髓性白血病（CML）的中枢神经系统（CNS）细胞危象是罕见的，由于许多全身疗法穿透血脑屏障（BBB）的能力有限，这给治疗带来了重大挑战。这一病例强调了有效治疗策略的必要性。病例报告：本病例报告描述了一名43岁的CML患者，在接受氟马替尼治疗时出现中枢神经系统细胞危象，随后骨髓复发。讨论：患者在接受blinatumomab和olverembatinib联合治疗以及每周鞘内化疗后，骨髓和中枢神经系统均获得完全缓解（CR）。结论：blinatumomab、olverembatinib联合鞘内化疗可能是CML进展的有效治疗策略，特别是在中枢神经系统受累的情况下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.